Tighe Wilhelmy with Velawcity here to discuss the latest developments in the Invokana lawsuit plaintiff attorneys should be aware of.
To preface these updates, I’d like to say there’s approximately (288) lawsuits filed in the MDL under Judge Brian Martinotti for plaintiffs who allegedly suffered ketoacidosis, or kidney damage, from Invokana.
Alright, let’s get started.
May 1st, 2017 - The court established an initial discovery plan addressing bellwether case selection protocol, scheduling and trial dates. There has been indication that bellwether trials could begin in September 2018. Great news for the plaintiff side.
May 5th, 2017 - The court made an order barring the filing of multi-plaintiff complaints, except for the ones that name a derivative plaintiff. Previous multi-plaintiff complaints will be separated.
May 17th, 2017 - The FDA issued a safety alert that Invokana and Invokamet present an increased risk of leg and foot amputations. This safety alert came as a result of (2) large clinical trials.The results showed that leg and foot amputations occurred roughly twice as much in patients who were treated with canagliflozin, which Invokana is, versus a placebo.
So let's think about that for a second. Invokana… Placebo… Invokana is twice as likely to result in leg or foot amputations.
May has clearly brought much activity to the Invokana lawsuit. If you have any questions regarding the Invokana litigation or acquisition of Invokana cases, please feel free to give us a call or visit our website. I’m Tighe Wilhelmy with Velawcity and thanks for watching.